Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Scottish Medicines Consortium accepts new follicular lymphoma treatment

The Scottish Medicines Consortium (SMC) has accepted obinutuzumab (Gazyvaro) for the treatment of follicular lymphoma when used alongside bendamustine.

The Scottish Medicines Consortium (SMC) has accepted obinutuzumab (Gazyvaro) for the treatment of follicular lymphoma when used alongside bendamustine. Follicular lymphoma is a type of cancer of the white blood cells. The new drug treatment was accepted was accepted by SMC for use alongside bendamustine in patients who don’t respond to, or whose condition gets worse, on other treatments.  Obintuzumab was considered through SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines to treat end of life and very rare conditions. Through the PACE process, patient groups and clinicians highlighted that follicular lymphoma is an incurable disease

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy